Bone Biologics (BBLG) Stock Statistics & Valuation Metrics

Bone Biologics has a market cap or net worth of $2.88M. The enterprise value is $85.58M.

Bone Biologics has 545,174 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bone Biologics’s return on equity (ROE) is -1.18 and return on invested capital (ROIC) is -121.11%.

The current PE Ratio of Bone Biologics is -0.35. Bone Biologics’s PEG ratio is 0.00.

In the last 12 months, Bone Biologics had revenue of 0.00 and earned -4.11M in profits. Earnings per share was -4.83.

In the last 12 months, operating cash flow was -3.75M and capital expenditures 0.00, giving a free cash flow of -3.75M billion.

Bone Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Bone Biologics upcoming earnings date is ―, TBA Not Confirmed.

Bone Biologics as a current ratio of 10.22, with Debt / Equity ratio of -95.39%

In the past 12 months, Bone Biologics has paid 0.00 in taxes.

Bone Biologics EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.46.

Bone Biologics has $2.75M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$2.75M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Bone Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―